Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Crame.

Yesterday, March 10, 2015, 98 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,617.00 to $5,999,989.08.

Highlighted Stocks Traded by Insiders:

Hyperion Therapeutics (HPTX) - FREE Research Report

Nash Christine A, who is SVP & Chief Commercial Officer at Hyperion Therapeutics, sold 9,900 shares at $29.63 on March 10, 2015. Following this transaction, the SVP & Chief Commercial Officer owned 19,003 shares meaning that the stake was reduced by 34.25% with the 9,900-share transaction.

The shares most recently traded at $32.95, up $3.32, or 10.09% since the insider transaction. Historical insider transactions for Hyperion Therapeutics go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares sold: 5,000

The average volume for Hyperion Therapeutics has been 169,800 shares per day over the past 30 days. Hyperion Therapeutics has a market cap of $620.3 million and is part of the health care sector and drugs industry. Shares are up 36.75% year-to-date as of the close of trading on Tuesday.

Hyperion Therapeutics, Inc., a commercial biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases and hepatology. Currently, there are 6 analysts who rate Hyperion Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HPTX - FREE

TheStreet Quant Ratings

rates Hyperion Therapeutics as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

TheStreet Recommends

Hyperion Therapeutics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Delphi Automotive (DLPH) - FREE Research Report

Sherbin David M, who is SVP, GC & Secretary at Delphi Automotive, sold 24,870 shares at $78.66 on March 10, 2015. Following this transaction, the SVP, GC & Secretary owned 79,186 shares meaning that the stake was reduced by 23.9% with the 24,870-share transaction.

The shares most recently traded at $77.10, down $1.56, or 2.02% since the insider transaction. Historical insider transactions for Delphi Automotive go as follows:

  • 4-Week # shares sold: 45,981
  • 12-Week # shares sold: 107,493
  • 24-Week # shares sold: 148,964

The average volume for Delphi Automotive has been 2.0 million shares per day over the past 30 days. Delphi Automotive has a market cap of $22.9 billion and is part of the consumer goods sector and automotive industry. Shares are up 6.77% year-to-date as of the close of trading on Tuesday.

Delphi Automotive PLC, together with its subsidiaries, manufacturers vehicle components; and provides electrical and electronic, powertrain, safety, and thermal technology solutions to the automotive and commercial vehicle markets worldwide. The stock currently has a dividend yield of 1.27%. The company has a P/E ratio of 17.6. Currently, there are 11 analysts who rate Delphi Automotive a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DLPH - FREE

TheStreet Quant Ratings

rates Delphi Automotive as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, notable return on equity and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full

Delphi Automotive Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Universal Insurance Holdings (UVE) - FREE Research Report

Callahan Scott P., who is Director at Universal Insurance Holdings, sold 6,000 shares at $25.01 on March 10, 2015. Following this transaction, the Director owned 5,000 shares meaning that the stake was reduced by 54.55% with the 6,000-share transaction.

The shares most recently traded at $24.24, down $0.77, or 3.18% since the insider transaction. Historical insider transactions for Universal Insurance Holdings go as follows:

  • 4-Week # shares bought: 1,500
  • 4-Week # shares sold: 41,000
  • 12-Week # shares bought: 1,500
  • 12-Week # shares sold: 107,000
  • 24-Week # shares bought: 1,500
  • 24-Week # shares sold: 260,520

The average volume for Universal Insurance Holdings has been 368,400 shares per day over the past 30 days. Universal Insurance Holdings has a market cap of $895.1 million and is part of the financial sector and insurance industry. Shares are up 18.29% year-to-date as of the close of trading on Tuesday.

Universal Insurance Holdings, Inc., through its subsidiaries, provides various property and casualty insurance products. It primarily underwrites homeowners' insurance products; and offers reinsurance intermediary brokerage services. The stock currently has a dividend yield of 1.66%. The company has a P/E ratio of 12.2. Currently, there are no analysts who rate Universal Insurance Holdings a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on UVE - FREE

TheStreet Quant Ratings

rates Universal Insurance Holdings as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

Universal Insurance Holdings Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null